Clinical Application of Non-Invasive Markers of Liver Fibrosis

Parsian, Hadi; Alizadeh, Maryam; Yahyapour, Yousef

doi:10.5772/55422

Cited by 2 publications

(2 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bonacini et al. developed a discriminant score ( Table 4 ) [ 60 ] for diagnosis of advanced fibrosis and cirrhosis by taking three parameters: platelets, ALT/AST ratio and PT which have positive correlation with histological scores and have 98% specificity but 46% sensitivity [ 60 ].…”

Section: Cytokines and Proteomic Markersmentioning

confidence: 99%

See 1 more Smart Citation

Liver Fibrosis: A Compilation on the Biomarkers Status and Their Significance During Disease Progression

et al. 2017

View full text Add to dashboard Cite

Liver fibrosis occurs in response to different etiologies of chronic liver injury. Diagnosing degree of liver fibrosis is a crucial step in evaluation of severity of the disease. An invasive liver biopsy is the gold standard method associated with pain and complications. Biomarkers to detect liver fibrosis include direct markers of extracellular matrix turnover and indirect markers as a reflection of liver dysfunction. Although a single marker may not be useful for successful management, a mathematical equation combining tests might be effective. The main purpose of this review is to understand the diagnostic accuracy of biomarkers and scoring systems for liver fibrosis. Advances in -omics approach have generated clinically significant biomarker candidates for liver fibrosis that need further evaluation.

show abstract

Section: Cytokines and Proteomic Markersmentioning

confidence: 99%

“… ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International normalized ratio. Data taken from [ 60 ]. …”

Section: Cytokines and Proteomic Markersmentioning

confidence: 99%

Liver Fibrosis: A Compilation on the Biomarkers Status and Their Significance During Disease Progression

et al. 2017

View full text Add to dashboard Cite

show abstract

Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?

Sanal¹

2015

WJG

View full text Add to dashboard Cite

Fatty liver is present in over ten percentage of the world population and it is a growing public health problem. Nonalcoholic fatty liver disease (NAFLD) is not a single disease, but encompasses a spectrum of diseases of different etiologies. It is difficult to find highly specific and sensitive diagnostic biomarkers when a disease is very complex. Therefore, we should aim to find relevant prognostic markers rather than accurate diagnostic markers which will help to minimize the frequency of liver biopsies to evaluate disease progression. There are several biomarker panels commercially available, however, there is no clear evidence that more sophisticated panels are better compared to simple criteria such as, presence of diabetes over five years, metabolic syndrome, obesity, obstructive sleep apnea, aspartate transaminase/alanine transaminase (ALT) ratio > 0.8 or ferritin levels > 1.5 times normal in patients with over six month history of raised ALT and/or ultrasonological evidence of fat in the liver. Currently the biomarker panels are not a replacement for a liver biopsy. However the need and benefit of liver biopsy in NAFLD is questionable because there is no convincing evidence that biopsy and detailed staging of NAFLD improves the management of NAFLD and benefits the patient. After all there is no evidence based treatment for NAFLD other than management of lifestyle and components of "metabolic syndrome".

show abstract

Clinical Application of Non-Invasive Markers of Liver Fibrosis

Abstract: Please use Adobe Acrobat Reader to read this book chapter for free. Just open this same document with Adobe Reader. If you do not have it, you can download it here. You can freely access the chapter at the Web Viewer here.

Cited by 2 publications

References 59 publications

Liver Fibrosis: A Compilation on the Biomarkers Status and Their Significance During Disease Progression

Liver Fibrosis: A Compilation on the Biomarkers Status and Their Significance During Disease Progression

Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?

Contact Info

Product

Resources

About